一项新研究发现：超过100万人在没有明显医疗原因的情况下仍在服用减肥药物一项大规模的新研究证实了人们的长期猜测：大量服用奥泽匹克（Ozempic）等减肥药物的人其实并没有相应的医疗需求。
A new study identified more than 1 million people taking weight-loss drugs without any apparent medical reason to do so. A large new study confirms what many people have long suspected: A sizable number of people taking drugs like Ozempic have no medical reason to do so.
该研究分析了超过9200万美国成年人的医疗记录，发现其中有110多万人正在服用GLP-1类减肥药物，但他们并未患有肥胖或糖尿病等需要使用这些药物的疾病。虽然研究人员并未探究人们服用这些药物的具体原因，但医生们表示，许多人可能是出于减肥的愿望，或是期望这些药物能带来其他潜在的好处而选择服用它们。
The study, an analysis of the medical records of more than 92 million U.S. adults, identified more than 1.1 million who were taking GLP-1 medications, without any record of an issue that would make them eligible, like obesity or diabetes. While the researchers didn’t examine why people took these medications, doctors said many people are probably using them simply to shed some pounds or in the hope they might deliver other, buzzy potential benefits.
“这种情况随处可见——人们公开分享自己使用这些药物的经历，有些效果不错，有些则效果不佳，”该研究的主要作者、纽约大学朗格尼健康中心（NYU Langone Health）的肥胖医学专家兼移植外科医生巴巴克·奥兰迪（Babak Orandi）博士说。他认为，这些积极的案例可能会激发人们的好奇心：“也许这些药物对我也有用吧。”
“You see it all over the place. You have people describing publicly their experience with these medications, some good, some bad,” Dr. Babak Orandi, an obesity medicine specialist and transplant surgeon at N.Y.U. Langone Health, and the lead author of the study, published Tuesday in the journal Obesity.
从技术层面讲，GLP-1类药物目前仅被批准用于治疗肥胖和糖尿病等病症；美国食品药品监督管理局（FDA）还批准了部分GLP-1药物用于预防心脏病发作和其他心血管疾病、治疗睡眠呼吸暂停（无论患者是否患有肥胖症），以及治疗2型糖尿病患者的肾脏疾病。
The positive anecdotes, he said, “may open up people’s curiosity to say, ‘Hey, maybe that could work for me.’” Technically, GLP-1s have only been approved for a few conditions, including obesity and diabetes. The Food and Drug Administration has also approved some GLP-1s to prevent heart attacks and other cardiovascular issues and to treat sleep apnea, both in people with obesity, and to treat kidney disease in those with type 2 diabetes.
奥泽匹克的“争议”：肥胖权益活动家弗吉尼亚·索尔-史密斯（Virginia Sole-Smith）的言行既激励了她的追随者，也引发了他们的愤怒；她揭露了体型较大的人所面临的偏见与歧视，尤其是来自医生和研究人员的歧视。
Age of Ozempic: The “fat activist” Virginia Sole-Smith is inspiring and infuriating her followers, and calling out the bias and discrimination faced by people in bigger bodies, especially from doctors and research scientists.
青少年男孩：长期以来，研究人员主要关注女孩的饮食失调问题及其治疗，但这一情况正在发生变化。两位专家分析了越来越多男孩出现饮食失调问题的原因。
Adolescent Boys: For the longest time, researchers focused on diagnosing and treating girls with eating disorders, but that is changing. Two experts share why increasingly boys have these disorders too.
更令人担忧的是：TikTok封禁了与“紧身裤”相关的标签（#legginglegs），但专家们表示，他们更担心社交媒体算法推荐的其他内容可能带来的负面影响。
A Bigger Concern: TikTok shut down the “legging legs” hashtag, but experts said they’re more worried about other content surfaced by social media algorithms.
对于这位患者来说，传统的心理治疗方法对她的治疗并无帮助，因此医生决定让她停止治疗——无论这会带来什么后果。然而，对于精神疾病采取“姑息性”（即不追求根治、仅缓解症状）的治疗方式，真的符合伦理道德吗？
Palliative Psychiatry: Treatment wasn’t helping her anorexia, so doctors allowed her to stop — no matter the consequences. But is a “palliative” approach to mental illness really ethical?
这些药物已经成为一种文化现象；公众对它们的讨论以及制药公司的激烈营销活动，引发了更广泛的关注。
But the drugs have become a cultural phenomenon, with the public discourse about them and the aggressive marketing of the medications generating far broader interest.